Abstract
Aim: Common Variable Immunodeficiency (CVID) is characterized by recurrent infections and chronic complications. While the infectious burden of CVID has been extensively studied, psychiatric comorbidities remain underrecognized. This study aimed to evaluate psychiatric symptom burden and associated factors in adult CVID patients receiving immunoglobulin replacement therapy.Methods: Sixteen adult patients with CVID were included in this cross-sectional study. Demographic and clinical data were collected retrospectively. Anxiety and depressive symptoms were assessed using the Hospital Anxiety and Depression Scale (HADS). Psychiatric diagnoses were classified according to DSM-5 criteria. Infection frequency before and after immunoglobulin replacement therapy was compared using the Wilcoxon signed-rank test. Associations between clinical variables and HADS scores were analyzed using nonparametric tests.Results: The mean age of the patients was 43.2 ± 14.9 years, and 50% were female. Immunoglobulin replacement therapy was associated with significant reductions in annual pneumonia (p=0.001), sinusitis (p=0.003), and antibiotic use (p=0.001). Clinically significant anxiety (HADS-A ≥11) was observed in 50% of patients, and depressive symptoms (HADS-D ≥11) in 56.3%. Eight patients (50%) met DSM-5 criteria for at least one psychiatric disorder. Anxiety and depressive scores were strongly correlated (ρ=0.939, p
Funding Information
  • No financial support was received for this study.

This publication has 19 references indexed in Scilit: